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In the recent Viewpoint article, Rook and
Stanford1 suggest that increased incidence
of allergies can be explained by decreased
exposure to T helper 1 (Th1)-inducing
pathogens and increased exposure to Th2-
inducing vaccines. Evidence for the former
is growing, however the latter, for the most
part, hinges on the assertion that current
vaccines, and pertussis vaccines in particu-
lar, are strong Th2 inducers. This is clearly
not the case. Indeed, a considerable body of
evidence has demonstrated that whole-cell
pertussis vaccines, similar to natural infec-
tion with Bordetella pertussis, selectively in-
duce Th1-type responses in infants2,3 and
mice4,5. Furthermore, the new acellular per-
tussis vaccines3, as well as diphtheria and
tetanus toxoids (K.H.G. Mills et al., un-
published) induce T cells with a mixed
Th1/Th2 cytokine profile in humans.
The article also suggests that the protec-
tive effect of most vaccines is largely medi-
ated by neutralizing antibodies, however
the contention that ‘Th2 responses are ade-
quate’ does not follow. This notion has
arisen from the simplistic dogma that Th1
cells only mediate cellular immunity and
Th2 cells stimulate humoral immunity.
However, it is clear that protection gener-
ated by killed or attenuated bacterial or
viral vaccines is most often mediated by
Th1 cells. Th1 cells mediate protective neu-
tralizing antibody responses against po-
liovirus6 and influenza virus7. Furthermore,
we have shown that protective immunity
induced with the pertussis whole-cell vac-
cine requires both humoral and cellular re-
sponses and is largely mediated by Th1
cells5,8,9.
Rook and Stanford claim that B. pertussis
is a ‘powerful Th2-inducing adjuvant’ and
assert that pertussis vaccination may in-
crease the incidence of Th2 disease. Experi-
mental evidence does not support this view.
The adjuvant properties of the whole-cell
pertussis vaccine are mediated, in part, by
lipopolysaccharide (LPS) and by residual
active pertussis toxin (PT)10,11. LPS en-
hances Th1 responses10, whereas PT en-
hances both Th1 and Th2 responses11. In
this situation the Th1 response is dominant,
which explains the polarized Th1 response
observed with the whole-cell pertussis vac-
cine. It has been demonstrated that purified
native PT can augment interleukin 4 (IL-4)
production and IgE responses to co-injected
antigens, but it also enhances interferon g
(IFN-g) production11. However, the results
obtained from systems where the response
to model antigens has been examined
should not be confused with the more com-
plex events following pertussis vaccination.
Booster immunization with certain acellu-
lar pertussis vaccines enhances Th2 re-
sponses and IgE specific for B. pertussis,
but is not associated with enhanced atopic
disease12 or IgE responses to common 
allergens in children (L. Nilsson et al., 
unpublished).
The authors claim that depriving the im-
mune system of the early input historically
provided by infection may lead to increased
allergy. In fact the reverse is true for active
infection with B. pertussis: allergic sensitiz-
ation is slightly increased in children with a
history of pertussis12,13. In this situation it is
the infectious ‘input’ and not input depri-
vation that is associated with allergy. This
cannot be explained by inadequate priming
of Th1 activity as convalescent infants de-
velop a Th1 response2, a result confirmed in
murine models of infection4,5,9. Whether the
immune system has evolved to ‘anticipate’
appropriate inputs in an appropriate se-
quence after birth has not yet been re-
solved. Our opinion is that this would be an
inflexible approach to immunity and that it
is more likely that each pathogen (and the
very large and diverse numbers of com-
mensals that comprise the normal flora) is
dealt with according to different criteria,
such as physiological niche, toxin produc-
tion and perhaps even danger.
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in the thymus and await experiments that
specifically address this issue.
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